Return-Path: Delivered-To: andrew@sterlingcal.com Received: from reseller401.webserversystems.com by reseller401.webserversystems.com with LMTP id iD7SAiV292jDewEAchKAPA (envelope-from ) for ; Tue, 21 Oct 2025 07:01:41 -0500 Return-path: Envelope-to: andrew@sterlingcal.com Delivery-date: Tue, 21 Oct 2025 07:01:41 -0500 Received: from r66.info.wiley.com ([172.82.209.66]:56048) by reseller401.webserversystems.com with esmtps (TLS1.2) tls TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384 (Exim 4.98.1) (envelope-from ) id 1vBB3c-00000000PlB-2P1y for andrew@sterlingcal.com; Tue, 21 Oct 2025 07:01:40 -0500 DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=info.wiley.com; s=wileypublishing; t=1761048089; bh=+mUX6ZC4hNSjzxdM2xJeLAkBbu370YXNck2uCOYXLT8=; h=From:Subject:Date:To:MIME-Version:Message-ID:List-Unsubscribe: Content-Type; b=Jy/UnLqx+leEycIeKhpNQG4CW3ks7HfbpBnr2HvPOFuP4fNX0MpZ0b3K/Iw/H8MGg UNYkOaf8a1HhbQqBl+EgCSC+XyX8HX+y71cZEW22RHeMzlUqkjUurSXZkuliCawsaI 8g3XY8CBtyrNQti+plweAR3F1rHFGwJgqgU1K35/q94/I8NFurXJ5Orb4zjDKf8IjE h2MPEs9AwAbh08uJ4EXM641mxtBFttL1f+HELwGy+0kIXYuky4BGP+DgqMxzdeAUm7 sUDZGeekr0PHXFawMWALRGqsxrcfExEEyHBsBj1BL05dA1Ns6iC52r7nO7XPWjj42r GBcRcCk/SsXMQ== X-MSFBL: N/Hq/SCYQL5B185/PyzGOYrSi0uPvyAHREych7gtMH0=|eyJiIjoid2lsZXlwdWJ saXNoaW5nXzE3Mi44Mi4yMDkuNjZfcHJvZC5qb2hud2lsZXltYXJrZXRpbmdfOWZ iYWY3ZjAtNTY3ZC00NWE5LWFiMmUtNDA4YzljNTZhNjc1IiwiciI6ImFuZHJld0B zdGVybGluZ2NhbC5jb20iLCJnIjoicHJvZC5qb2hud2lsZXltYXJrZXRpbmdfOWZ iYWY3ZjAtNTY3ZC00NWE5LWFiMmUtNDA4YzljNTZhNjc1IiwicmNwdF9tZXRhIjp 7ICJpbiI6ICJ3aWxleXB1Ymxpc2hpbmdfbWlkX3Byb2Q4IiwgInIiOiAiYW5kcmV 3QHN0ZXJsaW5nY2FsLmNvbSIsICJtIjogIjQxNGMwYTgzLWU3ZmQtNDkxZi1hZmY 5LTY2ZTJkZjc3NGM0MyIsICJkIjogIjczNjkxNTciLCAiaSI6ICIxQjZFMzRCODU yODJBMEFDMEE0OTBENDRAQWRvYmVPcmciIH19 Received: from [10.1.1.136] ([10.1.1.136:44301] helo=r67.info.wiley.com) by or2-prod1-mta-b-i-06dc65b8c12c587f7 (envelope-from ) (ecelerity 4.4.1.20033 r(msys-ecelerity:tags/4.4.1.0^0)) with ESMTP id 14/5B-20929-91677F86; Tue, 21 Oct 2025 12:01:29 +0000 From: "Wiley" Subject: =?utf-8?B?Tm93IE9uLURlbWFuZDogQWR2YW5jZWQgTksgYW5kIM6zzrQgVA==?= =?utf-8?B?IENlbGwgVGhlcmFweSBTdHJhdGVnaWVz?= Date: Tue, 21 Oct 2025 08:01:25 -0400 To: Reply-To: "Wiley" MIME-Version: 1.0 X-mailer: nlserver, Build 8.6.4 Message-ID: List-Unsubscribe: Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable X-Spam-Status: No, score=-0.5 X-Spam-Score: -4 X-Spam-Bar: / X-Spam-Flag: NO

If you are unable to view this message correctly, click here

Now On-Demand

Haploidentica= l hematopoietic stem cell transplantation (haplo-HSCT) offers life-saving p= otential for patients with acute myeloid leukaemia (AML), but the risk of g= raft-versus-host disease (GvHD) remains a major challenge. Our upcoming eve= nt explores a transformative approach to post-transplant therapy =E2=80=93 = leveraging the power of natural killer (NK) cells and =CE=B3=CE=B4 T cells = to maximize graft-versus-leukaemia (GvL) effects while minimizing GvHD.

Discover how donor grafts enriched with activated NK and =CE=B3=CE=B4 T cel= ls, engineered to enhance CD137L/CD137 signalling and NKG2D expression, can= overcome tumour resistance and reduce relapse rates. Learn from cutting-ed= ge research using spectral flow cytometry and a bidirectional mouse haplo-H= SCT model that reveals the mechanistic roles of these immune cells in anti-= leukaemic immunity.

Key Learnings:

•	Understand the dual role of donor T cells in haplo-H= SCT
•	Explore the therapeutic potential of NK and =CE=B3= =CE=B4 T cells in reducing relapse and GvHD
•	Analyze the bidirectional mouse model for mechanisti= c insights
•	Learn how spectral flow cytometry is used to charact= erize GvHD

Reserve your = spot today and be part of the future of immunotherapy in stem cell transpla= ntation.

Register now=

Speaker information

Ashley Connelly
Postdoctoral Scholar
University of Alabama
at Birmingham

Rob Welner
Associate Professor
University of Alabama
at Birmingham

This virtua= l seminar has been made possible through sponsorship from Agilent Technolog= ies.

= ; &nb= sp; =

= =

=C2=A9 John Wiley & Sons, Inc. All right= s reserved.